

Barbro K Linderholm

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7914240/publications.pdf>

Version: 2024-02-01

46
papers

1,623
citations

393982

19
h-index

301761

39
g-index

48
all docs

48
docs citations

48
times ranked

2517
citing authors

#	ARTICLE	IF	CITATIONS
1	Correlation of Vascular Endothelial Growth Factor Content With Recurrences, Survival, and First Relapse Site in Primary Node-Positive Breast Carcinoma After Adjuvant Treatment. <i>Journal of Clinical Oncology</i> , 2000, 18, 1423-1431.	0.8	237
2	p53 and vascular-endothelial-growth-factor (VEGF) expression predicts outcome in 833 patients with primary breast carcinoma. <i>International Journal of Cancer</i> , 2000, 89, 51-62.	2.3	136
3	Expression of Cyclin E and the Cyclin-Dependent Kinase Inhibitor p27 in Malignant Lymphomas—Prognostic Implications. <i>Blood</i> , 1998, 92, 770-777.	0.6	127
4	Tumor Specific VEGF-A and VEGFR2/KDR Protein are Co-expressed in Breast Cancer. <i>Breast Cancer Research and Treatment</i> , 2003, 82, 147-154.	1.1	104
5	An Autocrine VEGF/VEGFR2 and p38 Signaling Loop Confers Resistance to 4-Hydroxytamoxifen in MCF-7 Breast Cancer Cells. <i>Molecular Cancer Research</i> , 2008, 6, 1630-1638.	1.5	84
6	Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative. <i>Cancer Discovery</i> , 2021, 11, 2796-2811.	7.7	79
7	Comparative Proteome Analysis Revealing an 11-Protein Signature for Aggressive Triple-Negative Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2014, 106, djt376.	3.0	77
8	Molecular subtype and tumor characteristics of breast cancer metastases as assessed by gene expression significantly influence patient post-relapse survival. <i>Annals of Oncology</i> , 2015, 26, 81-88.	0.6	75
9	Pathological characterisation of male breast cancer: Results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program. <i>European Journal of Cancer</i> , 2017, 82, 219-227.	1.3	71
10	Prognostic Correlation of Basic Fibroblast Growth Factor and Vascular Endothelial Growth Factor in 1307 Primary Breast Cancers. <i>Clinical Breast Cancer</i> , 2003, 4, 340-347.	1.1	64
11	Retinoic acid receptor alpha is associated with tamoxifen resistance in breast cancer. <i>Nature Communications</i> , 2013, 4, 2175.	5.8	53
12	Activated ERK1/2 and phosphorylated oestrogen receptor $\hat{\pm}$ are associated with improved breast cancer survival in women treated with tamoxifen. <i>European Journal of Cancer</i> , 2006, 42, 1104-1112.	1.3	50
13	A comparison between young and old patients with triple-negative breast cancer: biology, survival and metastatic patterns. <i>Breast Cancer Research and Treatment</i> , 2020, 182, 643-654.	1.1	45
14	Diagnostic and prognostic role of plasma levels of two forms of cytokeratin 18 in patients with non-small-cell lung cancer. <i>European Journal of Cancer</i> , 2011, 47, 131-137.	1.3	38
15	Transcriptional Profiling of Breast Cancer Metastases Identifies Liver Metastasis—Selective Genes Associated with Adverse Outcome in Luminal A Primary Breast Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 146-157.	3.2	38
16	Immune gene expression and response to chemotherapy in advanced breast cancer. <i>British Journal of Cancer</i> , 2018, 118, 480-488.	2.9	37
17	Molecular profiling of male breast cancer — Lost in translation?. <i>International Journal of Biochemistry and Cell Biology</i> , 2014, 53, 526-535.	1.2	34
18	Male breast cancer precursor lesions: analysis of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program. <i>Modern Pathology</i> , 2017, 30, 509-518.	2.9	32

#	ARTICLE	IF	CITATIONS
19	Proteomics profiling identify CAPS as a potential predictive marker of tamoxifen resistance in estrogen receptor positive breast cancer. <i>Clinical Proteomics</i> , 2015, 12, 8.	1.1	31
20	Communicative challenges among physicians, patients, and family caregivers in cancer care: An exploratory qualitative study in Ethiopia. <i>PLoS ONE</i> , 2020, 15, e0230309.	1.1	23
21	Vascular endothelial growth factor is a strong predictor of early distant recurrences in a prospective study of premenopausal women with lymph-node negative breast cancer. <i>Breast</i> , 2008, 17, 484-491.	0.9	19
22	Vascular endothelial growth factor receptor 2 and downstream p38 mitogen-activated protein kinase are possible candidate markers of intrinsic resistance to adjuvant endocrine treatment in steroid receptor positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2011, 125, 457-465.	1.1	19
23	PAM50 Provides Prognostic Information When Applied to the Lymph Node Metastases of Advanced Breast Cancer Patients. <i>Clinical Cancer Research</i> , 2017, 23, 7225-7231.	3.2	17
24	A Population-based Study on the First Forty-Eight Breast Cancer Patients Receiving Trastuzumab (Herceptin®) on a Named Patient Basis in Sweden. <i>Acta Oncologica</i> , 2002, 41, 276-281.	0.8	16
25	A randomised feasibility/phase II study (SBC 2004-1) with dose-dense/tailored epirubicin, cyclophosphamide (EC) followed by docetaxel (T) or fixed dosed dose-dense EC/T versus T, doxorubicin and C (TAC) in node-positive breast cancer. <i>Acta Oncologica</i> , 2011, 50, 35-41.	0.8	16
26	Thrombospondin-1 expression in relation to p53 status and VEGF expression in human breast cancers. <i>European Journal of Cancer</i> , 2004, 40, 2417-2423.	1.3	13
27	Survival patterns of invasive lobular and invasive ductal breast cancer in a large population-based cohort with two decades of follow up. <i>Breast</i> , 2021, 59, 294-300.	0.9	12
28	Clinical outcome of patients with brain metastases from breast cancer - A population based study over 21 years. <i>Breast</i> , 2020, 50, 113-124.	0.9	10
29	Discordance of PIK3CA and TP53 mutations between breast cancer brain metastases and matched primary tumors. <i>Scientific Reports</i> , 2021, 11, 23548.	1.6	8
30	Impact of the first tumor response at eight weeks on overall survival in metastatic breast cancer patients treated with first-line combination chemotherapy. <i>Medical Oncology</i> , 2013, 30, 415.	1.2	7
31	Expression of Cyclin E and the Cyclin-Dependent Kinase Inhibitor p27 in Malignant Lymphomas – Prognostic Implications. <i>Blood</i> , 1998, 92, 770-777.	0.6	7
32	Improved survival for women with stage I breast cancer in south-east Sweden: A comparison between two time periods before and after increased use of adjuvant systemic therapy. <i>Acta Oncologica</i> , 2009, 48, 504-513.	0.8	6
33	Long-term safety and survival outcomes from the Scandinavian Breast Group 2004-1 randomized phase II trial of tailored dose-dense adjuvant chemotherapy for early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018, 168, 349-355.	1.1	5
34	Delta NT-proBNP predicts cardiotoxicity in HER2-positive breast cancer patients treated with trastuzumab. <i>Acta Oncologica</i> , 2021, 60, 475-481.	0.8	5
35	Alterations of the Immunoglobulin Heavy Chain Locus in Progressive B-cell Lymphomas. <i>Acta Oncologica</i> , 1998, 37, 193-200.	0.8	4
36	Sequencing of the Tumor Suppressor Gene TP 53. , 2006, 120, 389-402.		4

#	ARTICLE	IF	CITATIONS
37	The MAGIC survey in hormone receptor positive (HR+), HER2-negative (HER2 ⁻) breast cancer: When might multigene assays be of value?. <i>Breast</i> , 2017, 33, 191-199.	0.9	4
38	Evaluation of multiple transcriptomic gene risk signatures in male breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 98.	2.3	4
39	Weekly taxanes A leap forward or a minute progress?. <i>Acta Oncologica</i> , 2004, 43, 5-7.	0.8	3
40	Breaking Bad News in Cancer Care: Ethiopian Patients Want More Information Than What Family and the Public Want Them to Have. <i>JCO Global Oncology</i> , 2021, 7, 1341-1348.	0.8	3
41	Efficacy and tolerability of metronomic chemotherapy in patients with metastatic breast cancer – an international experience in West Sweden and in the South of Ireland.. <i>Cancer Treatment and Research Communications</i> , 2020, 25, 100237.	0.7	2
42	Personalised medicine and the decision to withhold chemotherapy in early breast cancer with intermediate risk of recurrence – a systematic review and meta-analysis. <i>European Journal of Clinical Pharmacology</i> , 2020, 76, 1199-1211.	0.8	2
43	Person and Family Centeredness in Ethiopian Cancer Care: Proposal for a Project for Improving Communication, Ethics, Decision Making, and Health. <i>JMIR Research Protocols</i> , 2020, 9, e16493.	0.5	2
44	Corrigendum to “Vascular endothelial growth factor is a strong predictor of early distant recurrences in a prospective study of premenopausal women with lymph-node negative breast cancer” [The Breast 17 (2008) 484–491]. <i>Breast</i> , 2009, 18, 142.	0.9	0
45	Cellular and Tissue Markers in Solid Tumors. , 2004, , 181-213.		0
46	Abstract OT2-30-01: Nordictrip, a translational randomized phase-3 study exploring the effect of the addition of capecitabine to carboplatinum-based chemotherapy in early “triple negative” breast cancer, ClinicalTrials.gov Identifier: NCT04335669. <i>Cancer Research</i> , 2022, 82, OT2-30-01-OT2-30-01.	0.4	0